Incubation (with antibiotic)

Slides:



Advertisements
Similar presentations
TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Advertisements

Animal Model PK/PD: A Tool for Drug Development
5/20/2015ISAP Is the cellular accumulation of antibiotics a predictive factor for intracellular efficacy ? Sandrine Lemaire Université catholique.
Eccmid 2003 Aminoglycosiden bij neonaten Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton Relationship between bacterial killing,
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Use of in vitro models to study the emergence of resistance Professor Inga Odenholt Department of Infectious Diseases University hospital, Malmö Sweden.
Hunting intracellular bacteria with antibiotics
Bacterial persistence
Setting-up a model of intracellular infection by Pseudomonas aeruginosa for the pharmacodynamic evaluation of antibiotic activity. J. Buyck1, O. Jolois2,
studies with Caco-2 cells and THP-1 macrophages
Activities of Daptomycin (DAP), Vancomycin (VAN) and Linezolid (LDZ) alone or in combination with Fusidic acid (FUS) in an in vitro dynamic model of.
A-052 Antibiotic (AB) activity against Pseudomonas aeruginosa (PA) with Normal or Mucoïd Phenotypes in an Artificial Sputum Medium (ASM) in vitro Biofilm.
Activity of tobramycin in combination with clarithromycin
Introduction Results Aim of the study Methods References Conclusion
Antifungal activity (MIC/MFC) against Candida spp.
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
Intracellular antibiotics and Listeria monocytogenes
Françoise Van Bambeke & Paul M. Tulkens
In vitro pharmacodynamic models for the study of antibiotic activity against bacterial biofilms Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire.
Mix with THP-1 macrophages Overnight bacterial suspension
Frédéric Peyrusson, Françoise Van Bambeke, Paul M. Tulkens
Accumulation, Release and Subcellular Distribution of the Peptide Deformylase Inhibitor GSK in Murine Macrophages (J774) and Human Monocytes (THP-1)
Activity of 9 antibiotics against intracellular forms of S. pneumoniae
P1058 Intracellular activity of antibiotics against a stable small colony variant (SCV) isolated from a CF patient in a model Calu-3 human airway epithelial.
Expression of Efflux system
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.
Revealing moxifloxacin activity against biofilms of S
Can efflux confer high levels resistance to meropenem (MEM) in Pseudomonas aeruginosa (Pa) clinical isolates? H. Chalhoub1, H. Rodriguez-Villalobos2,
Introduction & Purpose Results Conclusions
FUS, VAN and LZD injected twice (T0 and T12); DAP injected once (T0).
This poster will be made available for download after the meeting at :
Influence of antibiotic treatments on gene expression of RND efflux pumps in successive isolates of Pseudomonas aeruginosa collected from patients with.
Université catholique de Louvain
Introduction Results Aim Methods References Conclusion
Co-medications Improve Moxifloxacin (MXF) Activity in Models of Pneumococcal Naïve and Induced Biofilms (BF) N. M. Vandevelde1, M. Van Obbergh1, P.M. Tulkens1,
Background and objectives
Comparative in vitro activity of temocillin and other β-lactams
Activity and Pharmacodynamic (PD) Evaluation of Ceftazidime-Avibactam (CAZ-AVI) against Extracellular and Intracellular Forms of CAZ-susceptible and CAZ-resistant.
Inhibitors of type three secretion system [TTSS] protect against Pseudomonas aeruginosa cellular toxicity by inhibiting the transcription of TTSS Mailing.
Table 2: Percentage of cross resistance among tested antibiotics
Emilien Drouot, Paul M. Tulkens, Françoise Van Bambeke
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Extracellular activity Intracellular activity
Antibiotics in bone and joint infections
Abstract Results Methods Background Conclusions References
cellular accumulation (24h) Cstatic (LZD/RDZ ratio)
Apoptosis induced by aminoglycosides (AGs) in cultured cells : comparison between gentamicin (GEN) and amikacin (AMK) using incubated and electroporated.
52 - Antimicrobials Radezolid (RX-1741), a Novel Oxazolidinone, Accumulates Extensively within Human Macrophages and PMNs and Shows Activity towards.
Of a Pig-related ST-398 Methicillin-Resistant S. aureus (A-MRSA)
EV0626 Cellular pharmacokinetics of gepotidacin (GSK )
Abstract Results Aim of the study Methods Background Conclusions
Difference log CFU from time 0
DISCUSSION AND CONCLUSION
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.
INTRODUCTION METHODS CONCLUSIONS REFERENCES
1200 Brussels - Belgium Temocillin is not substrate for OprD2 porin from Pseudomonas aeruginosa H. Chalhoub1,
Electron microscopy: intracellular infection of THP-1 by S. aureus
Log extracellular concentration (mg/L)
Susceptibility of Pseudomonas aeruginosa (P. a
Activity of Moxifloxacin against Staphylococcus aureus in Models of Persistent Infections (Intracellular Survival, Biofilms) Mailing address: P.M. Tulkens.
Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
Intracellular antibiotics
Françoise Van Bambeke, Dr Sc. Pharm, Agr. Ens. Sup.
Intracellular models of infection to evaluate antibiotic activity
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
Setting-up of a 24 h model to evaluate the activity of antibiotics against intracellular forms of S. aureus infection C. Seral, M. Barcia-Macay, F. Van.
“Pulmonary infections”
Presentation transcript:

Incubation (with antibiotic) Pharmacodynamic evaluation of antibiotics and combinations against Pseudomonas aeruginosa (Pa) in broth and in human THP-1 monocytes Julien Buyck, Laetitia Garcia, Paul M. Tulkens and Françoise Van Bambeke Mailing address: F. Van Bambeke UCL 73.70 av. Mounier 73, 1200 Brussels – Belgium, francoise.vanbambeke@uclouvain.be Pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute, Brussels, Belgium. Abstract Results Materials & Methods Objectives: Pa is capable of invading epithelial and phagocytic cells (1), which may play an important role in the initiation and persistence of infections observed in cystic fibrosis. We have developed a model of intracellular infection of THP-1 cells by Pa and have used it to examine the activity of the main antipseudomonal antibiotics and combination in comparison with broth. Methods: We used ATCC PAO1 strain. For intracellular activity: phagocytosis was allowed for 2 h (bacteria/cells ratio: 10), extracellular bacteria were eliminated by incubation for 60 min with gentamicin at 100 mg/L, and infected cells incubated over a wide range of conc of antibiotics for 24 h. Activity against bacteria in broth was measured in parallel. Activity was expressed as change from the initial inoculum, and pharmacodynamic parameters [Emax, EC50 and Cstatic (see definition in Table)] were calcutated from the Hill equation of the dose-response. Combinations: Fractional Maximal Effect (FME) method, where AB conc. to be tested are calculated from EC50 and Emax to obtain 0.1, 0.3, 0.5, 0.7, 0.9-fold the Emax. Activity measured for combinations at conc. of AB1 and AB2 giving rise to of 0.1:0.9, 0.3:0.7, 0.5:0.5, 0.7:0.3; 0.9:0.1 effect ratio (2). FME (observed/theoretical effect) for synergy > 1; additivity ~ 1; indifference: < 1; antagonism: < effect of best AB alone. Results: The table shows that while all antibiotics were cidal in broth (Emax > -3 log CFU), their intracell. Emax was markedly reduced towards intracell. Pa, with fluoroquinolones the least affected. Cstatic remained close to the MIC except for aminoglycosides and CST (10-20-fold increase). Moreover, all combinations tested were synergistic against extracell. Pa (FME > 1) but additive or indifferent against internalized Pa. Conclusions: Antibiotics are considerably less active against intracellular forms of Pa compared to bacteria in broth. Combining antibiotics may prove useful to act upon intracellul. Pa though to a lesser extent than upon extracell. bacteria. Intracellular niches may contribute to the difficulty of eradicating Pa in vivo, and marked differences between antibiotic classes could be expected in this context. Activity of antibiotics against extracellular (blue) and intracellular (orange) P. aeruginosa. Bacterial strain and susceptibility testing. P. aeruginosa strain ATCC PAO1 was used. MICs were measured by microdilution in MH broth supplemented with 10% of fetal calf serum. Pharmacodynamics of combinations. Fractional Maximal Effect (observed/theoretical effect): synergy > 1; additivity ~ 1; indifference: < 1; antagonism: < effect of best AB alone Pharmacodynamics of antibiotics alone. Extracellular activity was measured in MHB; intracellular activity were measured as described previously in a model of PAO1-infected THP-1 cells (3). PD parameters (Emax [max CFU decrease extrapolated for infinitely large concentration]; EC50 [concentration for which E = ½ Emax]) were calcutated from the Hill equation of the dose-response. 9 mL RPMI + (1 h, 37°c) Opsonization 1 mL human serum 750,000 cells/mL MOI 10 Phagocytosis (2 h) Extracellular Wash GEN 100 µg/ml (1 h) nucleus actin 5 to 7x105 CFU/mg prot. Time 0 4µM We used the Fractional Maximal Effect (FME) method, where antibiotic concentrations to be tested are calculated from EC50 and Emax to obtain 0.1, 0.3, 0.5, 0.7, 0.9-fold the Emaxa. Activity was measured for combinations at concentration of AB1 and AB2 giving rise to of 0.1:0.9, 0.3:0.7, 0.5:0.5, 0.7:0.3; 0.9:0.1 effect ratio (2). P. aeruginosa Incubation (with antibiotic) (24 h) Antibiotics MIC (mg/L) Extracellular Intracellular Emaxa (log cfu) EC50b (mg/L) Static conc.c mg/L (xMIC) EC50b (mg/L) Gentamicin 0.5 -4.0 ± 0.4 0.5 (1) -1.6 ± 0.2 6.5 11.5 (23) Tobramycin -4.9 ± 0.2 0.3 0.3 (0.6) -0.9 ± 0.2 3.0 11.2 (22.4) Piperacillin/ tazobactam 16 -4.6 ± 0.7 22.3 17.7 (1.1) -0.6 ± 0.2 6.3 (0.4) Cefepime 2 >-5 4.4 2.9 (1.5) -1.4 ± 0.2 2.0 4.6 (2.3) Ceftazidime 4 5.3 4.9 (1.2) -1.3 ± 0.1 0.6 1.3 (0.3) Meropenem 1 1.16 0.8 (0.8) -1.7±0.2 0.6 (0.6) Colistin 0.4 (0.2) -0.9±0.1 0.4 1.1 (0.6) Ciprofloxacin 0.125 0.2 0.1 (0.8) -3.0±0.3 0.3 (2.4) Levofloxacin -4.1 ± 0.4 0.7 (1.4) -2.6±0.2 0.4 (0.8) a relative maximal efficacy: CFU decrease (log10 units) at time 24 h from the corresponding original inoculum, as extrapolated for an infinitely large antibiotic concentration b drug concentration giving a response half-way between E0 and Emax C static concentration (relative potency): concentration resulting no apparent bacterial growth (number of CFU identical to the initial inoculum), as determined by graphical intrapolation. CA= FMEA.EC50A 1-FMEA CB= FMEB.EC50B 1-FMEB Results Activity of combinations against extracellular (upper panel) and intracellular (lower panel) P. aeruginosa. ciprofloxacin/colistin colistin/tobramycin meropenem/ciprofloxacin meropenem/tobramycin Background and aim Pseudomonas aeruginosa, one of the main causative agents of pneumonia in cystic fibrosis patients, is an opportunistic intracellular bacterium. About half of the strains is indeed able to invade and survive within human phagocytes (1). The treatment of such infections is challenging since the activity of antibiotics may differ markedly between the extracellular and intracellular milieu. In this context, we have we have set up a model of P. aeruginosa-infected human monocytes THP-1 cell line and used it to determine the intracellular activity of antibiotics currently used in the clinics in comparison with their activity in broth. We have also examined whether combining antibiotics may improve their activity against intracellular vs. extracellular P. aeruginosa. Extracellularly All antibiotics tested were bactericidal (Emax > - 3 log) All static concentrations were close to the MIC Intracellularly Emax were reduced, with only ciprofloxacin remaining cidal Tobramycin potency was reduced (10-fold increase in Cstatic) Extracellularly All combinations were synergistic at least when combined at concentrations generating 0.5 FME for individual drugs Intracellularly Combinations globally rather show additive effets Conclusions References All antibiotics tested show reduced activity intracellularly, but to different extents : Tobramycin shows a reduction in its maximal efficacy and relative potency. Meropenem, ciprofloxacin and colistin also show a reduced maximal efficacy but no marked change in relative potency. Only ciprofloxacin reaches a bactericidal maximal effect. Combining these antibiotics proves highly effective towards extracellular P. aeruginosa, and to al lesser extent against intracellular bacteria. Yet, this strategy may help to prevent emergence of resistance. (1) Kierbel et al., Mol. Biol. Cell 2005,16: 2577-85 (2) Nguyen et al., AAC 2009, 53: 1443–9 (3) Barcia-Macay et al., AAC 2006, 50:841-51 ACKNOWLEDGEMENTS: We thank M.C. Cambier, V. Mohymont and C. Misson for excellent technical assistance. This work was supported by the BioWin program (Region Wallone; Belgium). This poster will be made available for download after the meeting: http://www.facm.ucl.ac.be/posters.htm